IQVIA Holdings, Inc. · NYSE:IQV

IQVIA — Quintiles — Jefferies 2015 Global Healthcare Conference

15 slides from IQVIA's conference presentation, Jun 2, 2015

  1. Slide 1: Jefferies 2015 Global Healthcare Conference

    Jefferies 2015 Global Healthcare Conference June 2, 2015 © Copyright 2014 Quintiles NYSE: Q

  2. Slide 2: Forward Looking Statements and Use of Non-GAAP Financial Measures

    Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements refl

  3. Slide 3: Quintiles: Leader in BioPharma Services

    Quintiles Leader in BioPharma Services Growing Markets Differentiated Deep & Diverse Service Offerings Customer & Relationships Relationships Clear Industry Leader Financial Strength and Execution Momentum 3

  4. Slide 4: Strategic Agenda

    Strategic Agenda • Profitable growth at above market rates • Investments leveraging our scale • World class customer relationship management • Productivity, delivery & quality • Top leadership and people development Connecting insights with superior delivery for better outcomes 4

  5. Slide 5: Track Record of Profitable Growth and Consistency

    Track Record of Profitable Growth and Consistency Long-term performance underpinned with a diversified customer portfolio Service Revenues Adjusted EBITDA(1) ’11 – ’14 CAGR = 8.1% ’11 – ’14 CAGR = 13.7% 4,400 $4,166 $4,191 800 $720 $728 $3,808 $3,692 $3,295 $612 3,300 600 $544 $490 $ Millions $ Mill

  6. Slide 6: Financial Highlights

    Financial Highlights Q1 Financial Highlights Other Highlights Constant Currency  Announcement of Clinical Laboratory 10.5% Net New Business Growth Services Joint Venture with Quest Diagnostics Constant Currency Revenue 8.4% Growth(1)  Completion of $2.75bn debt refinancing • Extends maturities and

  7. Slide 7: Attractive and Growing Market

    Attractive and Growing Market ~$200bn total market across both segments with increasing outsourcing penetration which drives estimated growth of 6% – 8% per year from 2014 – 2017 Approval Phase Commercial Phase I Phase II Phase III Healthcare Delivery IV Product Development Services Integrated Healt

  8. Slide 8: Market drivers

    Market drivers We understand the needs of biopharma and how the industry is evolving Simplify the complex – Improve Increase R&D Provide global investigator & productivity scientific patient access expertise Using real- Increasing Increasing world data & demand for importance of analytics to evidenc

  9. Slide 9: Deep Customer Relationships

    Deep Customer Relationships Largest backlog in industry with diversification and sustainability • Helped develop or commercialize all of 2014’s top-75 best-selling drugs on the market • Worked with the top-20 biopharma companies ranked by 2013 revenues in each of last 12 years • 11 customer accounts

  10. Slide 10: The Quintiles Difference

    The Quintiles Difference The integration of our assets creates differentiated value Global harmonized Deep scientific, therapeutic, best in class Technology & informatics & regulatory expertise processes & workforce 950 >23 Quintiles Infosario™ Platform Medical doctors Prime sites Planning & Design

  11. Slide 11: Differentiated market leader

    Quintiles Differentiated market leader Strong free cash flow Best in industry operating margins Deep and diverse customer relationships Consistent long term financial performance First mover advantage with Clinical Development Informatics technology Largest backlog in Market leader in industry Produ

  12. Slide 12: Appendix

    Appendix QUINTILES’ 12

  13. Slide 13: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation Adjusted EBITDA Reconciliation LTM period ended (In Thousands) 3/31/2015 2014 2013 2012 2011 Non-GAAP Adjusted EBITDA: Net Income Attributable to Quintiles Transnational Holdings Inc. $352,598 $356,383 $226,591 $177,546 $241,772 Net income (loss) attributable to noncon

  14. Slide 14: Constant Currency Reconciliation Service Revenues and Income from Operations

    Constant Currency Reconciliation Service Revenues and Income from Operations (millions of dollars) Three Months Ended March 31 Year on Year Growth Exchange Exchange Consolidated Actual Impact Constant Actual Impact Constant Service Revenues $ 1,030.0 $ (59.0) $ 1,089.0 2.5% (5.9%) 8.4% Income from O

  15. Slide 15: Reconciliation of Net Income to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS

    Reconciliation of Net Income Attributable to Quintiles to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS Three Months Ended March 31 (millions of dollars) 2015 1 2014 1 EPS EPS Net Income Attributable to Quintiles $ 86.4 $ 0.68 $ 90.2 $ 0.68 Restructuring Costs 5.3 0.04 1.0 0.01 Adjustment to

Quintiles — Jefferies 2015 Global Healthcare Conference on 6ix